Reprint

From a Molecule to a Drug: Chemical Features Enhancing Pharmacological Potential

Edited by
July 2022
234 pages
  • ISBN978-3-0365-4753-4 (Hardback)
  • ISBN978-3-0365-4754-1 (PDF)

This book is a reprint of the Special Issue From a Molecule to a Drug: Chemical Features Enhancing Pharmacological Potential that was published in

Chemistry & Materials Science
Medicine & Pharmacology
Summary

This book collects contributions published in the Special Issue “From a Molecule to a Drug: Chemical Features Enhancing Pharmacological Potential” and dealing with successful stories of drug improvement or design using classic protocols, quantum mechanical mechanistic investigation, or hybrid approaches such as QM/MM or QM/ML (machine learning). In the last two decades, computer-aided modeling has strongly supported scientists’ intuition to design functional molecules. High-throughput screening protocols, mainly based on classical mechanics’ atomistic potentials, are largely employed in biology and medicinal chemistry studies with the aim of simulating drug-likeness and bioactivity in terms of efficient binding to the target receptors. The advantages of this approach are quick outcomes, the possibility of repurposing commercially available drugs, consolidated protocols, and the availability of large databases. On the other hand, these studies do not intrinsically provide reactivity information, which requires quantum mechanical methodologies that are only applicable to significantly smaller and simplified systems at present. These latter studies focus on the drug itself, considering the chemical properties related to its structural features and motifs. Overall, such simulations provide necessary insights for a better understanding of the chemistry principles that rule the diseases at the molecular level, as well as possible mechanisms for restoring the physiological equilibrium.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
SARS-CoV-2; benzoic acid derivatives; gallic acid; molecular docking; reactivity parameters; selenoxide elimination; one-pot; imine-enamine; reaction mechanism; DFT calculations; selenium; anti-inflammatory drugs; QSAR; pain management; cyclooxygenase; multitarget drug; cannabinoid; neuropathic pain; clopidogrel; NMR study; oxone; peroxymonosulfate; sodium halide; thienopyridine; drug discovery; precision medicine; pharmacodynamics; pharmacokinetics; coronavirus SARS-CoV-2; COVID-19; 3-chymotrypsin-like protease; pyrimidonic pharmaceuticals; molecular dynamics simulations; binding free energy; β-carrageenan; antioxidant activity; Box-Behken; extraction; Eucheuma gelatinae; physic-chemistry; rheology; quercetin; quercetin 3-O-glucuronide; cisplatin; nephrotoxicity; cytoprotection; lithium therapy; neurocytology; toxicology; neuroprotection; chemoinformatics; big data; methadone hydrochloride; pharmaceutical solutions; drug compounding; high performance liquid chromatography; stability study; microbiology; fucoidan; alginate; L-selectin; E-selectin; MCP-1; ICAM-1; molecular docking; THP-1 macrophage; monocyte migration; protein binding; breast milk; M/P ratio; statistical modeling; molecular descriptors; chromatographic descriptors; affinity chromatography; anti-ACE; anti-DPP-IV; gastrointestinal digestion; in silico; molecular docking; molecular dynamics; paramyosin; pharmacokinetics; seafood; target fishing; n/a